卡博替尼联合阿替利珠单抗对比索拉非尼治疗晚期肝细胞癌(COSMIC-312):一项多中心、开放标签、随机、3期试验
COSMIC-312是一项多中心、开放标签、随机3期试验,纳入既往未接受系统治疗的晚期肝细胞癌患者,比较卡博替尼联合阿替利珠单抗与索拉非尼的疗效。联合组中位无进展生存期6.8个月 vs 索拉非尼组4.2个月(HR 0.63,99% CI 0.44-0.91,p=0.0012),中位总生存期15.4个月 vs 15.5个月(HR 0.90,96% CI 0.69-1.18;p=0.44)。作者认为联合方案可能成为部分晚期肝细胞癌患者的治疗选择,但需进一步研究。
要点
- 联合组中位无进展生存期6.8个月 vs 索拉非尼组4.2个月(HR 0.63,99% CI 0.44-0.91,p=0.0012)。
- 联合组中位总生存期15.4个月 vs 索拉非尼组15.5个月(HR 0.90,96% CI 0.69-1.18;p=0.44)。
- 联合组治疗相关5级事件6例(1%),索拉非尼组1例(<1%),单药卡博替尼组1例(<1%)。
核心结论
- 卡博替尼联合阿替利珠单抗可能成为部分晚期肝细胞癌患者的治疗选择,但需进一步研究。
研究设计与样本
- COSMIC-312为开放标签、随机、3期试验,在32个国家178个中心入组≥18岁、不可根治或局部区域治疗的晚期肝细胞癌且既往未接受系统抗癌治疗的患者。
- 患者按2:1:1随机分配至卡博替尼40 mg口服每日一次联合阿替利珠单抗1200 mg静脉注射每3周一次、索拉非尼400 mg口服每日两次或单药卡博替尼60 mg口服每日一次。
- 随机分层因素为疾病病因、地理区域和肝外疾病或大血管侵犯的存在。
- 双主要终点为盲态独立放射学委员会按RECIST 1.1评估的前372例随机分配至联合组或索拉非尼组患者的无进展生存期(PFS ITT人群)和所有随机分配至联合组或索拉非尼组患者的总生存期(ITT人群)。
- 数据截止2021年3月8日,分析2018年12月7日至2020年8月27日随机分配的前837例患者:联合组432例、索拉非尼组217例、单药卡博替尼组188例。
主要发现
- PFS ITT人群中位随访15.8个月(IQR 14.5-17.2),ITT人群中位随访13.3个月(10.5-16.0)。
- 联合组中位无进展生存期6.8个月(99% CI 5.6-8.3)vs 索拉非尼组4.2个月(2.8-7.0),HR 0.63(99% CI 0.44-0.91,p=0.0012)。
- 联合组中位总生存期(中期分析)15.4个月(96% CI 13.7-17.7)vs 索拉非尼组15.5个月(12.1-不可估计),HR 0.90(96% CI 0.69-1.18;p=0.44)。
- 最常见的3或4级不良事件为丙氨酸氨基转移酶升高(联合组38/429例[9%] vs 索拉非尼组6/207例[3%] vs 单药卡博替尼组12/188例[6%])、高血压(37例[9%] vs 17例[8%] vs 23例[12%])、天冬氨酸氨基转移酶升高(37例[9%] vs 8例[4%] vs 18例[10%])和掌跖红斑感觉异常(35例[8%] vs 17例[8%] vs 16例[9%])。
- 治疗相关严重不良事件发生于联合组78例(18%)、索拉非尼组16例(8%)、单药卡博替尼组24例(13%)。
关键数值与推荐
- 联合组治疗相关5级事件6例(1%):脑病、肝衰竭、药物性肝损伤、食管静脉曲张出血、多器官功能障碍综合征和肿瘤溶解综合征。
- 索拉非尼组治疗相关5级事件1例(<1%):一般身体健康状况恶化。
- 单药卡博替尼组治疗相关5级事件1例(<1%):胃肠道出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. METHODS: COSMIC-312 is an open-label, randomised, phase 3 trial that enrolled patients aged 18 years or older with advanced hepatocellular carcinoma not amenable to curative or locoregional therapy and previously untreated with systemic anticancer therapy at 178 centres in 32 countries. Patients with fibrolamellar carcinoma, sarcomatoid hepatocellular carcinoma, or combined hepatocellular cholangiocarcinoma were not eligible. Tumours involving major blood vessels, including the main portal vein, were permitted. Patients were required to have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), Barcelona Clinic Liver Cancer stage B or C disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, adequate organ and marrow function, and Child-Pugh class A. Previous resection, tumour ablation, radiotherapy, or arterial chemotherapy was allowed if more than 28 days before randomisation. Patients were randomly assigned (2:1:1) via a web-based interactive response system to cabozantinib 40 mg orally once daily plus atezolizumab 1200 mg intravenously every 3 weeks, sorafenib 400 mg orally twice daily, or single-agent cabozantinib 60 mg orally once daily. Randomisation was stratified by disease aetiology, geographical region, and presence of extrahepatic disease or macrovascular invasion. Dual primary endpoints were progression-free survival per RECIST 1.1 as assessed by a blinded independent radiology committee in the first 372 patients randomly assigned to the combination treatment of cabozantinib plus atezolizumab or sorafenib (progression-free survival intention-to-treat [ITT] population), and overall survival in all patients randomly assigned to cabozantinib plus atezolizumab or sorafenib (ITT population). Final progression-free survival and concurrent interim overall survival analyses are presented. This trial is registered with ClinicalTrials.gov, NCT03755791. FINDINGS: Analyses at data cut-off (March 8, 2021) included the first 837 patients randomly assigned between Dec 7, 2018, and Aug 27, 2020, to combination treatment of cabozantinib plus atezolizumab (n=432), sorafenib (n=217), or single-agent cabozantinib (n=188). Median follow-up was 15·8 months (IQR 14·5-17·2) in the progression-free survival ITT population and 13·3 months (10·5-16·0) in the ITT population. Median progression-free survival was 6·8 months (99% CI 5·6-8·3) in the combination treatment group versus 4·2 months (2·8-7·0) in the sorafenib group (hazard ratio [HR] 0·63, 99% CI 0·44-0·91, p=0·0012). Median overall survival (interim analysis) was 15·4 months (96% CI 13·7-17·7) in the combination treatment group versus 15·5 months (12·1-not estimable) in the sorafenib group (HR 0·90, 96% CI 0·69-1·18; p=0·44). The most common grade 3 or 4 adverse events were alanine aminotransferase increase (38 [9%] of 429 patients in the combination treatment group vs six [3%] of 207 in the sorafenib group vs 12 [6%] of 188 in the single-agent cabozantinib group), hypertension (37 [9%] vs 17 [8%] vs 23 [12%]), aspartate aminotransferase increase (37 [9%] vs eight [4%] vs 18 [10%]), and palmar-plantar erythrodysaesthesia (35 [8%] vs 17 [8%] vs 16 [9%]); serious treatment-related adverse events occurred in 78 (18%) patients in the combination treatment group, 16 (8%) patients in the sorafenib group, and 24 (13%) in the single-agent cabozantinib group. Treatment-related grade 5 events occurred in six (1%) patients in the combination treatment group (encephalopathy, hepatic failure, drug-induced liver injury, oesophageal varices haemorrhage, multiple organ dysfunction syndrome, and tumour lysis syndrome), one (<1%) patient in the sorafenib group (general physical health deterioration), and one (<1%) patient in the single-agent cabozantinib group (gastrointestinal haemorrhage). INTERPRETATION: Cabozantinib plus atezolizumab might be a treatment option for select patients with advanced hepatocellular carcinoma, but additional studies are needed. FUNDING: Exelixis and Ipsen.
引用
- Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022. PMID: 35798016. doi:10.1016/S1470-2045(22)00326-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。